The analgesic effect generally starts within minutes of intravenous injection, and within 10-15 minutes of intramuscular injection. The peak effect is reached within 30-60 minutes of intravenous or intramuscular injection, and the duration of action is 3-4 hours, similar to sedatives, meperidine, and pentazocine. How much is the dosage and cost of Butorphanol tartrate injection? What are the common questions?

Dosage for Use:

The intravenous injection dose is 1mg (1 bottle), and the intramuscular injection dose is 1-2mg (1-2 bottles). If necessary, the drug can be repeated once every 3-4 hours. There is no sufficient clinical medical material to strongly recommend a single dose exceeding 4mg (4 bottles). Or as directed by a physician.

Common Questions:

Caution should be exercised in patients who have repeatedly used anesthetic analgesics and are opiate tolerant.

Caution should be exercised or not used in patients with brain damage and increased intracranial pressure.

The initial dosing interval for patients with kidney disease should be increased to 6-8 hours until the response is good, and then the dosage should be adjusted according to the patient’s response rather than a fixed regimen.

Caution should be exercised in patients with myocardial infarction, atrial dysfunction, and incomplete coronary artery function. Discontinue immediately if hypertension occurs.

Butorphanol tartrate injection can cause respiratory depression, especially in patients who are taking CNS stimulants or have CNS diseases or respiratory function defects, and should be used with caution.

It is strictly forbidden to drink alcohol when taking Butorphanol tartrate injection. The potential for human dependence after short-term administration of Butorphanol tartrate injection in rodents is less than that of sedatives, but according to reports in recent years, whether it is small animals or humans, long-term, frequent, and excessive use of Butorphanol tartrate.

Butorphanol tartrate is a key metabolic substance that excites K-opioid peptide protein kinase, and has both excitatory and antagonistic effects on U-protein kinase. It interacts indirectly with this protein kinase in the central nervous system (CNS), fully exerting its pharmacological value, including analgesic effects. In addition to analgesic effects, its effects on the CNS include reducing spontaneous inspiration of the respiratory tract, coughing, stimulation of the vomiting center, pupillary constriction, sedation, and other pharmacological values. Its efficacy may be achieved through non-CNS action mechanisms. Such as changing the resistance and capacitor of the cardiovascular (nervous) system, supporting the respiratory muscle exercise, digestive tract metabolism, muscle exercise, and bladder sphincter activity.